The ethical issues in disclosing genetic risk for multiple sclerosis (MS) are complex and multifaceted, involving concerns about privacy, psychological impact, discrimination, informed consent, and the broader implications for families and society. Genetic risk disclosure means informing an individual that…
Multiple sclerosis (MS) is a chronic condition that affects the central nervous system, and for many people living with it, heat can be a major trigger for symptom flare-ups. This happens because heat can slow down nerve signals that are…
Climate extremes, particularly heat waves, have a profound impact on multiple sclerosis (MS) disease activity, often worsening symptoms and increasing the risk of complications. MS is a neurological condition characterized by damage to the brain and spinal cord, where nerve…
Cost-sharing reforms have the potential to improve outcomes for underserved multiple sclerosis (MS) patients by reducing financial barriers to accessing essential disease-modifying therapies (DMTs), but the effectiveness of such reforms depends on how they are designed and implemented. Multiple sclerosis…
The role of **financial toxicity** in adherence to multiple sclerosis (MS) therapies is significant and multifaceted. Financial toxicity refers to the negative financial impact and stress that patients experience due to the high costs associated with medical treatments, including medications,…
Relapse treatment, particularly in neurological disorders like multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), can potentially be optimized by incorporating neuroprotective co-therapies alongside traditional immunosuppressive or immunomodulatory treatments. This approach aims not only to reduce the frequency and…
When considering the impact of long-term corticosteroid pulses on brain volume in multiple sclerosis (MS), it’s essential to delve into the complex interplay between corticosteroids, the immune system, and the brain’s structure. Multiple sclerosis is a chronic autoimmune disease characterized…
Standardized cannabinoid formulations have the potential to improve pain management in multiple sclerosis (MS) patients without causing significant cognitive harm, but this depends heavily on the specific composition, dosing, and delivery methods used. MS is a complex neurological condition characterized…
Cannabis use in multiple sclerosis (MS) has been studied extensively for its effects on two major symptoms: spasticity and cognition. Spasticity refers to the involuntary muscle stiffness and spasms that many people with MS experience, which can significantly impair movement…
Integrated lifestyle programs can indeed deliver additive benefits to disease-modifying therapies (DMTs) in managing multiple sclerosis (MS) by addressing symptoms, improving overall health, and potentially influencing disease progression through complementary mechanisms. These programs typically combine exercise, nutrition, mental health care,…